Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "disease free survival" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Analysis of disease free survival in cutaneous melanoma patients subject to sentinel lymph node biopsy
Autorzy:
Łobaziewicz, Wojciech
Szloch, Joanna
Wajda, Justyna
Legkiy, Oleksandr
Marczyk, Elżbieta
Wysocki, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1391682.pdf
Data publikacji:
2020
Wydawca:
Index Copernicus International
Tematy:
cutaneous melanoma
disease free survival
lymphadenectomy
sentinel lymph node biopsy
SNB
Opis:
Introduction: Cutaneous melanoma is estimated for 2% of malignant neoplasms occurring in humans. It is characterized by a high level of malignancy and low sensitivity to cytostatic drugs. The incidence of cutaneous melanoma is increasing in Poland. The lymphatic system is the most common route of dissemination of this neoplasm. The appearance of a sentinel node biopsy technique has made it possible to identify patients with a regionally advanced disease. It is a minimally invasive method with a small percentage of complications. Aim: Analysis of disease free survival (DFS) in cutaneous melanoma patients with sentinel lymph node biopsy. Material and methods: The analysis included 222 patients with cutaneous melanoma treated in the Department of Oncological Surgery in 2010–2015, who underwent a sentinel node biopsy. The study group consisted of 136 women and 86 men, the average age of patients was 59 years. Patients were qualified for sentinel node biopsy based on clinical evaluation and ultrasound of regional lymph nodes. The average follow-up was 25.1 months. About 2 hours before surgery, patients received a radioisotope, then lymphoscintigraphy SPECT was performed. Additionally, they were administered the Patent Blue dye in the operating room. Results: The sentinel node was identified in 217 patients (98%), and the average sentinel nodes were 2.25. Twenty-seven patients (12%) had a metastasis in sentinel nodes. In this group, the duration of symptom free survival was significantly shorter. Sentinel node status and age of the patient were independent factors affecting the prognosis of disease free survival. Conclusions: Sentinel node biopsy is a precise method to identify patients with cutaneous melanoma who have metastasis to regional lymph nodes, as well as the most important prognostic factor.
Źródło:
Polish Journal of Surgery; 2020, 92, 3; 15-21
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer
Autorzy:
Sieńko, J.
Teliga-Czajkowska, J.
Przytula, E.
Czajkowski, K.
Smolarczyk, R.
Nowis, D.
Powiązania:
https://bibliotekanauki.pl/articles/2085041.pdf
Data publikacji:
2019
Wydawca:
Instytut Medycyny Wsi
Tematy:
Peroxiredoxin-1
PRDX-1
ovarian cancer
overall survival
disease free survival
Opis:
Introduction and objective. Peroxiredoxin-1 (PRDX-1) belongs to a family of antioxidant enzymes and has proved to be a versatile molecule regulating cell growth, differentiation and apoptosis. PRDX1-regulated signaling pathways play an important role in the progression and metastasis of human tumours, especially in breast, esophageal and lung cancers. The aim of the study was to evaluate the expression of PRDX-1 in ovarian cancer tissues, and to test the clinical value of PRDX-1 as a prognostic factor in this malignancy. Materials and method. PRDX-1 expression was assessed by automated immunohistochemistry in tumours taken from 55 patients with ovarian cancer during primary surgery. Specimen were formalin-fixed and preserved in paraffin-embedded blocks. The results were correlated with clinicopathological data. Results. A high expression of PRDX-1 was observed in 20% of cases, and was associated with worse compliance to chemotherapy protocol (P<0.002), worse response to chemotherapy (P<0.04), and higher levels of CA 125 after the 1st line treatment (P<0.004). PRDX-1 positive subjects had a significantly lower 5-year disease-free survival (9.1% vs. 42.6%, P<0.01) and a lower 5-year overall survival (9.1% vs. 56.7%; P<0.002). Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01). Conclusion. Results of the study show that PRDX-1 expression in tumour tissues can be another biomarker of prognosis in patients with ovarian cancer.
Źródło:
Annals of Agricultural and Environmental Medicine; 2019, 26, 3; 415-419
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies